Third Trial For Teva’s Laquinimod Hinges On SPA From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva will initiate a third clinical trial testing the oral multiple sclerosis drug laquinimod after finalizing a special protocol assessment with FDA.